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Abstract
Cardiovascular diseases (CVD) are highly prevalent in older adults and represent a major geriatric health-care concern. 
Management of CVD in older patients may be challenging due to specific geriatric issues, such as frailty and multi-morbidity, 
which may influence patients’ outcomes. In this clinical context, diagnostic and therapeutic strategies should target those 
outcomes that have higher priority in geriatric health care, including disability prevention and quality of life. Older adults 
with CVD should be offered a reasonably optimized treatment, customized to the individual’s frailty level and functional 
status. Yet, most clinical trials excluded comorbid and frail patients and evidence to support CVD management in this vulner-
able population is lacking. Therefore, a geriatric approach is needed in cardiovascular medicine, characterized by a holistic, 
patient-centered perspective focusing on functional status and quality of life. With a view to promote the geriatric approach 
in the management of older patients with CVD, the EuGMS Special Interest Group (SIG) on Cardiovascular Medicine was 
founded in 2018, consisting of a network of geriatricians with an extensive expertise in geriatric cardiovascular medicine. 
The present position paper aims to present the Cardiovascular SIG and illustrate its main purposes and action programs.
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Cardiovascular diseases (CVD) are a major health issue in 
older adults [1, 2]. Over the past decades, the continuous 
increase in life expectancy has been accompanied by a paral-
lel increase in the prevalence of CVD, since age represents 
one of the main risk factors for these conditions [3]. Moreo-
ver, advances in medical care and technology have decreased 
cardiac-related mortality, which implies that patients with 
CVD survive for longer periods and often reach advanced 
ages. In everyday clinical practice in Europe, patients with 
arterial hypertension, acute coronary syndromes, heart fail-
ure, and atrial fibrillation are usually older than 70, 75, and 
80 years of age, respectively [4, 5], and these conditions 
commonly co-occur. As a consequence, the majority of 
individuals suffering from CVD are geriatric patients and 
there is a need for a geriatric approach in cardiovascular 
medicine.
The diagnostic and therapeutic management of CVD in 
the geriatric population may be challenging due to specific 
clinical, social, and ethical issues related to aging.
First, 55–98% of older adults present with multi-morbid-
ity [2, 6], defined as the presence of two or more concurrent 
chronic diseases. Multi-morbidity increases the likelihood of 
adverse outcomes, such as hospital readmission, disability, 
and death [7, 8]. Also, some of these comorbidities, such 
as renal insufficiency, are very frequent in patients with 
advanced age and influence CVD management and prog-
nosis [9]. Patients with multi-morbidity are often excluded 
from randomized controlled trials, thus limited evidence is 
available to guide clinical decisions in this context [6, 10, 
11]. Moreover, multi-morbidity usually leads to polyphar-
macy, as many of those chronic conditions may nowadays 
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be treated by drugs. Polypharmacy increases the risk for 
adverse drug reactions, which may account for hospital 
admissions, functional decline, or death [12].
Second, in addition to multi-morbidity, specific geriatric 
syndromes may coexist with CVD and affect health-care 
goals, the whole process of care and outcomes [3, 8, 13, 
14]. For example, frailty is a complex functional syndrome 
due to age-related medical and biological alterations, char-
acterized by a state of increased vulnerability to external 
stressors [15], which strongly increases the risk of nega-
tive health outcomes in CVD [16]. Fried and colleagues 
proposed a clinical phenotype of frailty as a well-defined 
syndrome with biological basis [15]. They postulated that 
the clinical manifestations of frailty are related in a mutually 
exacerbating cycle of negative energy balance, sarcopenia, 
and diminished strength and tolerance for exertion. Indeed, 
several studies have demonstrated that frail older adults are 
more likely to experience falls, disability, hospitalization, 
and death compared with those who are not frail [17–20]. 
Other examples of geriatric syndromes include impaired 
cognition, delirium, gait disorders, and urinary incontinence, 
all of which may complicate CVD management [21–23]. 
Indeed, falls risk and the sequelae of traumatic intracranial 
bleeding are frequently cited as a major reason for not treat-
ing atrial fibrillation with oral anticoagulants, thus poten-
tially increasing the probability of thromboembolism. As 
well as in multi-morbidity, once again no clear evidence is 
available to guide therapeutic decisions in complex older 
patients presenting with geriatric syndromes [10, 24, 25]. 
Also, older patients with acute CVD may present delirium 
and this has an important short-term and long-term clinical 
relevance. In all these situations, management and decision-
making in clinical practice highly vary according to the cli-
nician’s judgment and experience.
Thirdly, multi-morbidity, polypharmacy, frailty, and other 
geriatric syndromes can also influence the clinical presenta-
tion of CVD, which is frequently atypical in older individu-
als. Indeed, common presenting symptoms of CVD such as 
chest pain, dyspnea, or exercise intolerance may be absent, 
and cardiac diseases may manifest with confusion, falls, or 
loss of functional autonomy as predominant symptom [26]. 
As a result, CVD is commonly underestimated and treatment 
delays may occur.
Finally, older people may vary in their treatment and 
health outcome preferences, e.g., giving priority to quality 
of life instead of length of life or avoidance of drug-related 
side effects instead of long-term, often secondary, preven-
tion therapies.
These complex patients therefore challenge the appli-
cability of traditional CVD management, including guide-
line- and evidence-based medicine. Most current guide-
lines do not adequately reflect medical decisions in these 
vulnerable geriatric individuals [3, 10, 11, 27], which is a 
consequence of the fact that most clinical trials excluded 
comorbid or frail patients. Indeed, most randomized 
clinical trials have recruited patients in good physical 
and mental conditions and, hence, are poorly represent-
ative of the majority of older patients in the real world 
[27–29]. Additionally, most clinical trials did not address 
those outcomes that may have higher priority for older 
adults, e.g., functional decline, quality of life, and symp-
tom relief [8, 11]. Therefore, cardiologists often plan their 
care irrespective of the presence of the above-mentioned 
geriatric syndromes. Cardiologists also face ethical and 
economic dilemmas when using advanced technologies 
in complex, geriatric patients with limited life expectancy, 
e.g., heart failure devices or transcatheter aortic valve 
implantation (TAVI) [18, 30]. Better strategies and tools 
are urgently needed to estimate benefits and risks in the 
individual older patient, based on his or her health status 
and preferences. Yet, the purported absolute risk benefit 
ratio for treatment options may be difficult to estimate, in 
the presence of competing geriatric conditions that may 
determine outcomes more strongly than CVD and that are 
not included in commonly used risk assessment tools [1].
The limited generalizability of guidelines, together 
with concerns on the clinical benefits of interventions and 
potential harmful side effects, contributes to the frequent 
underdiagnoses and undertreatment of CVD in older adults. 
Indeed, real-world registries report that older patients with 
cardiovascular diseases are systematically undertreated in 
parallel with their increasing burden of comorbidities [7]. 
These findings suggest that, although not intended, an agis-
tic approach that is “an attitude that discriminates, sepa-
rates, stigmatizes, or otherwise disadvantages older adults 
on the basis of chronological age” is still present in practice 
[31, 32]. Yet, in some cases, it is also possible that very old 
people are overtreated for CVD, if single disease-oriented 
guidelines and advanced therapeutic options are reflexively 
applied in older adults with frailty, multi-morbidity, and lim-
ited life expectancy.
CVD account for a high proportion of deaths in the geri-
atric population [2] and may profoundly affect global health 
status of older patients, impacting on physical and cogni-
tive functioning, functional abilities, and quality of life [33, 
34]. Therefore, diagnosing and treating CVD in older people 
do not only reduce mortality, but may also contribute to 
counteract functional decline and improve quality of life, 
which are considered to be a priority in geriatric health care. 
Indeed, treatment benefits are not only maintained, but prob-
ably enhanced in older cardiac patients, compared with the 
younger ones [35].
Given the above considerations, older cardiac patients 
should not be excluded by age from advanced diagnostic 
and therapeutic options. Yet, they should be offered a rea-
sonably optimized treatment, customized to the individual’s 
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frailty and functional status and mainly aimed at preventing 
functional decline and improving quality of life.
To tailor CVD management to the individual’s need, 
different patient profiles might be defined on the basis of 
functional level and autonomy for daily activities and dif-
ferent health-care plans could be developed according to the 
patient’s profile [27]. For patients with a preserved func-
tion profile, diagnostic and therapeutic strategies should 
be similar to those proposed for younger old adults. For 
patients with a functional decline without a significant loss 
of autonomy in daily life, a more detailed geriatric assess-
ment is needed to define the benefit/risk balance of the vari-
ous therapeutic strategies. Lastly, for patients with a signifi-
cant loss of function and autonomy, therapeutic strategies 
should be thoroughly reassessed, including deprescribing 
when appropriate.
Alongside with functional autonomy, physical perfor-
mance may also help to assess patients’ prognosis and guide 
the diagnostic and therapeutical approach. Indeed, strong 
evidence supports the role of physical performance meas-
ures to predict adverse outcomes in older adults with CVD. 
In particular, grip strength and lower extremities’ perfor-
mance (e.g., Short Physical Performance Battery) have been 
identified as predictors of adverse events in these patients 
[36–38]. Moreover, grip strength and gait speed seem to 
modify the association between blood pressure and mortal-
ity [39, 40]. Therefore, physical performance tests should 
be included in the assessment of older patients with CVD, 
with a view to optimizing risk stratification and tailor medi-
cal management.
In view of these complexities, a geriatric approach is 
needed in cardiovascular medicine. In particular, the cardio-
logical perspective focusing on “disease-specific outcomes” 
has to be shifted in the geriatric population to a holistic, 
patient-centered perspective with a focus on outcomes 
including symptom relief, functional status, and quality of 
life.
To date, geriatricians rarely play an active role in the 
management of older cardiac patients, as reported in the 
EuGMS survey on TAVI [41]. Conversely, a geriatric assess-
ment has proven useful in these patients, showing a greater 
predictive value for functional decline than commonly used 
surgical risk scores [18]. To support a geriatric approach 
in this context, the EuGMS developed a protocol for com-
prehensive geriatric assessment in candidates for TAVI 
[42], showing a potential benefit on the prediction of post-
operative adverse outcomes [43]. More generally, there is an 
urgent need for designing and performing clinical trials in 
old adults focusing on the subgroups of patients who have 
always been excluded from these studies, i.e., those with 
significant loss of functionality, high degree of frailty, and 
loss of autonomy [44].
With a view to further promoting the geriatric approach 
in the management of older patients with CVD, the EuGMS 
Special Interest Group (SIG) on Cardiovascular Medicine 
was founded in 2018. The Cardiovascular SIG involves a 
network of geriatricians from excellence centers all over 
Europe—i.e., geriatric syncope unit, geriatric hypertension 
centers, geriatric heart failure clinic, etc.—with an extensive 
expertise in geriatric cardiovascular medicine. The present 
position paper aims to present the Cardiovascular SIG and 
illustrate its action program.
The main purposes of the SIG may be outlined as follows:
• to disseminate the geriatric principles and knowhow in 
the context of CVD management;
• to promote a comprehensive multidimensional approach 
to CVD in older patients, taking into account the impact 
of cognitive and functional impairments and frailty on 
diagnostic and therapeutic interventions;
• to interact with cardiologists to optimize the diagnostic 
and therapeutic pathways, with the final aim of targeting 
geriatric goals such as functional autonomy and quality 
of life;
• to increase the influence of geriatrics and geriatricians 
in the planning of care and decision-making processes 
dealing with older cardiac patients;
• to connect and cooperate with other Scientific Societies 
(e.g., European Society of Cardiology, European Society 
of Hypertension…), to elaborate clinical recommenda-
tions and guidelines to optimize older patients’ care;
• to develop and support research projects dealing with 
CVD in older adults, aiming to address missing research 
topics on geriatric cardiovascular medicine, with particu-
lar reference to frail, older patients;
• to implement currently available risk assessment tools 
and improve their predictive accuracy in older adults, to 
support clinical decision-making in invasive procedures, 
e.g., TAVI, chronic treatment of hypertension and heart 
failure, etc.
In the view of adopting the geriatric approach in routine 
clinical practice, the following milestones of the geriatric 
evaluation should be incorporated in cardiovascular diag-
nostic and therapeutic pathways:
1. performing a comprehensive geriatric assessment, 
including functional status, cognitive and physical per-
formance, falls history, and orthostatic blood pressure 
measurement;
2. identifying geriatric impairments and syndromes (e.g., 
frailty) that may influence individual’s health outcomes;
3. addressing polypharmacy, to review medications and 
optimize prescribing;
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4. incorporating patient’s perspectives and goals in the 
management of advanced CVD;
5. favouring the development of organizational models 
providing the continuity of care for older, frail patients 
with chronic cardiac conditions, e.g., from hospitals to 
rehabilitation facilities, home care, and palliative care 
units.
A 2011 White Paper in the Journal of the American Col-
lege of Cardiology stated that “Mainstream cardiology has 
become, de facto, geriatric cardiology, but it still lacks a 
systematic approach that incorporates age-related complexi-
ties into clinical decision-making” [3]. In the perspective of 
a further, rapid expansion of the population of older patients 
with chronic cardiovascular diseases, the EuGMS SIG on 
Cardiovascular Medicine calls for a geriatric approach to 
CV medicine to answer the complex needs of older patients 
with CVD. In particular, we aim at implementing the clinical 
management of older patients with CVD by introducing the 
main concepts of geriatric medicine into their routine cardio-
logical care. This process may be regarded as the integration 
between the two specialties, to combine the knowledge and 
skills of cardiology and the multidimensional approach of 
geriatrics.
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